ScholarIQanswers from OpenAlex
AdventHealth Orlando
InstitutionResearch output, impact & collaborations
AdventHealth Orlando is a institution indexed in ScholarIQ from OpenAlex.
What is known about AdventHealth Orlando?
ScholarIQrecord summary
AdventHealth Orlando is a research organisation in Orlando, US. OpenAlex records 5,027 works and 183,028 citations for it. 1,863 researchers list it as their most recent affiliation.
How many works does AdventHealth Orlando have?
ScholarIQindexed works
AdventHealth Orlando has 5,027 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does AdventHealth Orlando have?
ScholarIQcitation count
AdventHealth Orlando has 183,028 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at AdventHealth Orlando?
ScholarIQresearcher count
AdventHealth Orlando has 1,863 researchers in the ScholarIQ index.
What is the average h-index at AdventHealth Orlando?
ScholarIQavg h-index
AdventHealth Orlando has an average h-index of 42.8 in OpenAlex.
What is the ROR of AdventHealth Orlando?
ScholarIQror
The ROR for AdventHealth Orlando is on the source record.
What is the OpenAlex record for AdventHealth Orlando?
ScholarIQopenalex
The OpenAlex for AdventHealth Orlando is on the source record.
What is the Wikidata of AdventHealth Orlando?
ScholarIQwikidata
The Wikidata for AdventHealth Orlando is on the source record.
Who are the most-cited researchers behind AdventHealth Orlando?
ScholarIQtop researchers by citations
What are the most-cited papers on AdventHealth Orlando?
ScholarIQmost cited works
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou
Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih‐Hsin Yang, Brett Hughes, H. Léna, Denis Moro‐Sibilot, Alessandra Bearz, Santiago Viteri, Tarek Mekhail, Alexander I. Spira, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, Ali Zeaiter, Dong‐Wan Kim
How much of the research on AdventHealth Orlando is open access?
ScholarIQopen access share
83%OPEN ACCESS